Ica was only 24 years old when she was diagnosed with non-special type grade 2 breast cancer with IHC results showing ER and PR hormone positive characteristics, HER2 +2, with a Ki67 proliferation rate of 70-80%. Given her very young age, she sought an alternative to radical mastectomy and decided to use ECCT. Due to the positive hormone characteristics and moderate malignancy, the use of ECCT for this type relatively has a slow response and needs to be aided by anti-hormone medication. Ica then only used the ECCT device and consumed anti-hormone medication from her doctor. The initial reaction was relatively slow, tending to stagnate, but as time went on, the mass slowly began to shrink until it was clear after 3 years of use. Other lumps, such as benign masses and cysts, also disappeared. Her breasts returned to normal, as if nothing had happened. After 5 years, her condition remained healthy and normal, and her breasts remained clear.
Ica was still 24 years old when she was diagnosed with breast cancer 5 years ago. Ultrasound results showed multiple lesions in both breasts, including solid/malignant, benign, and cystic tendencies. PET results showed malignant activity in the left breast. Biopsy results of the suspected malignant lump showed Non-Special Type grade 2 cancer with IHC results indicating ER and PR hormone positive characteristics, HER2 +2, with a Ki67 proliferation rate of 70-80%, prone to spreading.
Medically, a radical mastectomy is required, followed by chemotherapy and/or radiotherapy, and follow-up with anti-hormone and anti-HER2 targeted therapies.
Her mother panicked, and Ica was just as panicked. The problem was that she was only 24 years old, just finished college. Was there no other alternative to avoid radical mastectomy?
Ica and her mother came to C-Care to consult on the possibility of using an ECCT device to avoid mastectomy. It was explained that her type was not one that “matched” with ECCT. Types with moderate to low malignancy, with positive hormone characteristics and positive HER2 (triple positive), are the types that respond LEAST FAVORABLY to ECCT. ECCT is most suitable for types with high malignancy (grade 3) with triple negative characteristics (ER, PR hormones negative, HER2 negative), and high proliferation rates are relatively not an issue. Ica’s case was contrary to the characteristics that respond well to ECCT.
However, her mother insisted on trying ECCT, hoping to avoid surgery. Given that the lesions were still relatively small (<2 cm) and thus inflammation could still be controlled, Ica was finally allowed to use the ECCT device, with the condition that she would still need to receive anti-hormone medication and, if possible, anti-HER2 medication from her doctor. Thankfully, her oncologist agreed to postpone the mastectomy and provide anti-hormone medication, and was willing to continue monitoring her progress.
While using the device, Ica, accompanied by her mother, regularly underwent check-ups and controls with her doctor every month. The first 6 months of development were relatively stagnant, consistent with the low-grade characteristic with ECCT. After 8-9 months, ultrasound results finally showed both malignant and benign lesions shrinking. After 3 years of use, she was declared CLEAR; all lesions, whether malignant, benign, or cystic, were no longer detectable by ultrasound.
Ica used the 2nd generation ECCT device, which had been revised from the previous generation to suppress inflammation, as inflammation is a major factor in cancer progression and spread. Combination with targeted drugs to suppress triggering factors (hormones and HER2) is still necessary because so far the ECCT device cannot suppress the activity of body hormones and HER2. To achieve this, electromagnetic field modulation needs to be developed that can activate or deactivate all receptors on the cell membrane related to cancer cell activity.
After 5 years, Ica’s condition is healthy and normal. Both her breasts are normal, as if nothing had ever happened.
May Ica stay healthy. (WS)
